NCT02689167View on ClinicalTrials.gov

Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma

PHASE2UnknownINTERVENTIONAL
Enrollment

226

Participants

Timeline

Start Date

February 19, 2016

Primary Completion Date

February 29, 2024

Study Completion Date

February 29, 2024

Conditions
Kidney NeoplasmsMetastatic Renal Cell Cancer
Interventions
DRUG

Sunitinib

Trial Locations (1)

25030

CHU Besancon, Besançon

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Centre Hospitalier Universitaire de Besancon

OTHER

NCT02689167 - Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter